Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience.
In order to determine associations between the major histocompatibility complex (MHC) and the development of clozapine-induced agranulocytosis, HLA typing was performed in a group of 42 clozapine-treated patients, of whom 11 had developed this adverse reaction. Among the patients with agranulocytosis, 7 (63%) were of Ashkenazi Jewish background and 4 (37%) were non-Jewish. An association between the HLA-B38, -DR4, -DQw3 haplotype and clozapine-induced agranulocytosis was found in all Jewish cases (7/7; 100%); in contrast only 4 of 21 (19%) Jewish control (nonagranulocytic) patients carried this haplotype. Among non-Jewish patients the HLA-DR2, -DQw1 haplotype was present in 4 of 4 (100%) patients with clozapine-induced agranulocytosis and in only 3 of 10 (30%) ethnically matched control patients. Our results indicate that gene products within the MHC could be involved in clozapine-mediated haematological toxicity.
Yunis
J J
JJ
Division of Immunogenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lieberman
J
J
Yunis
E J
EJ
D000380:Agranulocytosis / Q000139:chemically induced / Q000235:genetics* / Q000276:immunology; D003024:Clozapine / Q000009:adverse effects*; D006239:Haplotypes; D006801:Humans; D007585:Jews / Q000235:genetics*; D008285:Major Histocompatibility Complex / Q000235:genetics*; D014481:United States
D003024:Clozapine